Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

NCT00889382 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00889382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00889382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Lead sponsor
Astellas Pharma Inc
Phase
Phase 1/2
Overall status
Completed
Start date
August 5, 2009
Completion date
August 25, 2014
Enrollment
152 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, solid tumors